MENU
+Compare
BBP
ETF ticker: NYSE ARCA
AS OF
Dec 18, 04:01 PM (EDT)
Price
$60.45
Change
-$1.89 (-3.03%)
Net Assets
21.81M

BBP stock forecast, quote, news & analysis

Category: @Health
BBP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
A.I.Advisor
a Summary for BBP with price predictions
Dec 17, 2024

BBP in -3.88% downward trend, declining for three consecutive days on December 13, 2024

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where BBP declined for three days, in of 277 cases, the price declined further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on December 10, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on BBP as a result. In of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for BBP turned negative on December 11, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at .

BBP moved below its 50-day moving average on December 12, 2024 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for BBP crossed bearishly below the 50-day moving average on December 17, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BBP's RSI Indicator exited the oversold zone, of 22 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BBP advanced for three days, in of 315 cases, the price rose further within the following month. The odds of a continued upward trend are .

BBP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 222 cases where BBP Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), Biogen (NASDAQ:BIIB), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Intra-Cellular Therapies (NASDAQ:ITCI), BioCryst Pharmaceuticals (NASDAQ:BCRX).

Industry description

The investment seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Products Index. Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with at least one drug therapy approved by the U.S. Food and Drug Administration ("FDA") for marketing.

Market Cap

The average market capitalization across the Virtus LifeSci Biotech Products ETF ETF is 15.26B. The market cap for tickers in the group ranges from 87.21M to 151.69B. AMGN holds the highest valuation in this group at 151.69B. The lowest valued company is BLUE at 87.21M.

High and low price notable news

The average weekly price growth across all stocks in the Virtus LifeSci Biotech Products ETF ETF was 8%. For the same ETF, the average monthly price growth was 32%, and the average quarterly price growth was 133%. ASND experienced the highest price growth at 8%, while SWTX experienced the biggest fall at -9%.

Volume

The average weekly volume growth across all stocks in the Virtus LifeSci Biotech Products ETF ETF was -3%. For the same stocks of the ETF, the average monthly volume growth was -47% and the average quarterly volume growth was -17%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 64
P/E Growth Rating: 75
Price Growth Rating: 53
SMR Rating: 80
Profit Risk Rating: 70
Seasonality Score: 20 (-100 ... +100)
View a ticker or compare two or three
BBP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
501 Madison Avenue, Suite 501New YorkNew York
Phone
(212) 593-4383
Web
N/A